Basic Information
DIANEAL PD-2 PERITONEAL DIALYSIS SOLUTION WITH 2.5% DEXTROSE
SOLUTION, STERILE
Regulatory Information
SIN05748P
April 8, 1991
General Sale List
Therapeutic
INTRAPERITONEAL
August 10, 2023
May 30, 2025
XB05DA
Company Information
BAXTER HEALTHCARE (ASIA) PTE LTD
BAXTER HEALTHCARE (ASIA) PTE LTD
Active Ingredients
Strength: 5.08 mg/100 ml
Strength: 538 mg/100 ml
Strength: 25.7 mg/100 ml
Strength: 448 mg/100 ml
Strength: 2.5 g/100 ml
Detailed Information
Contraindications
**Contraindications** DIANEAL is contraindicated in patients with: - pre-existing severe lactic acidosis. - uncorrectable mechanical defects that prevent effective PD or increase the risk of infection. - documented loss of peritoneal function or extensive adhesions that compromise peritoneal function.
Indication Information
**AMBU-FLEX Container For Peritoneal Dialysis** **Indications and Usage** Peritoneal dialysis is indicated for patients in acute or chronic renal failure when nondialytic medical therapy is judged to be inadequate. It may also be indicated in the treatment of certain fluid and electrolyte disturbances, and for patients intoxicated with certain poisons and drugs. However, for many substances other methods of detoxification have been reported to be more effective than peritoneal dialysis. **ULTRABAG System For Continuous Ambulatory Peritoneal Dialysis (CAPD)** **Indications and Usage** Dianeal PD-2 peritoneal dialysis solutions in UltraBag containers are indicated for use in chronic renal failure patients being maintained on continuous ambulatory peritoneal dialysis when nondialytic medical therapy is judged to be inadequate.